# Breye Therapeutics

> Clinical-stage ophthalmology biotech that raised €67.5 million in an oversubscribed Series A.

## Why it is interesting

Large European Series A funding oral therapies for retinal disease, with primary-source confirmation.

## Profile

- **Latest funding:** Series A — €67.5M (September 29, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-09-30
- **Latest funding investors:** Mission BioCapital, Novo Holdings, Sound Bioventures

## Key facts

- Sep 29, 2026: €67.5M Series A
- Funding supports Phase II development of danegaptide

## Funding history

- Series A · €67.5M · September 29, 2026
  Source: https://www.globenewswire.com/news-release/2026/09/29/3370426/0/en/breye-therapeutics-raises-67-5-million-in-over-subscribed-series-a-financing.html

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** September 30, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/breye-therapeutics